Last reviewed · How we verify
MEDI7734
At a glance
| Generic name | MEDI7734 |
|---|---|
| Sponsor | Amgen |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis (PHASE1)
- A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI7734 CI brief — competitive landscape report
- MEDI7734 updates RSS · CI watch RSS
- Amgen portfolio CI